Literature DB >> 9787740

Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988.

S L Stafford1, A Perry, V J Suman, F B Meyer, B W Scheithauer, C M Lohse, E G Shaw.   

Abstract

OBJECTIVE: To establish prognostic factors for recurrence and outcome of surgical treatment, with or without postoperative radiation therapy, in patients with meningiomas.
MATERIAL AND METHODS: From 1978 through 1988, 581 patients underwent initial resection of a previously untreated primary meningioma at Mayo Clinic Rochester. In this study cohort, the outcome and prognostic factors associated with radiographic progression-free survival were analyzed.
RESULTS: Gross total resection (GTR) of the meningioma was accomplished in 80% of patients; the other 20% underwent less than GTR. Perioperative mortality within 10 days was 1.6%. Overall survival was significantly decreased from that for an age- and sex-matched cohort from the US white population. Progression-free survival at 5 and 10 years was 88% and 75%, respectively, in patients who underwent GTR and 61% and 39%, respectively, in those who underwent less than GTR. Multivariate analysis showed that age younger than 40 years, male sex, less than GTR, optic nerve involvement, and 4 or more mitotic figures per 10 high-power fields were associated with decreased progression-free survival. The 581 patients had 106 first recurrences. A trend toward improved progression-free survival was noted after first recurrence when irradiation with or without operation was used in comparison with only surgical treatment (P = 0.058).
CONCLUSION: With only operative treatment of meningioma, the 10-year recurrence rate was 25% in patients who had GTR and 61% in those who had less than GTR. These results emphasize the need for long-term follow-up and for consideration of adjuvant radiation therapy. Patients treated at the time of recurrence seem to benefit from radiation therapy with or without surgical resection. Factors associated with recurrence were (1) less than GTR, (2) involvement of the anterior visual pathway, (3) age younger than 40 years, and (4) increased mitotic index.

Entities:  

Mesh:

Year:  1998        PMID: 9787740     DOI: 10.4065/73.10.936

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  60 in total

1.  Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.

Authors:  Ali Afshar-Oromieh; Frederik L Giesel; Heinz G Linhart; Uwe Haberkorn; Sabine Haufe; Stephanie E Combs; Dino Podlesek; Michael Eisenhut; Clemens Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-05       Impact factor: 9.236

2.  Impaired survival and long-term neurological problems in benign meningioma.

Authors:  Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

Review 3.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

Review 4.  Fractionated radiotherapy for intracranial meningiomas.

Authors:  Vinai Gondi; Wolfgang A Tome; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

Review 5.  Stereotactic radiosurgery for benign meningiomas.

Authors:  Orin Bloch; Gurvinder Kaur; Brian J Jian; Andrew T Parsa; Igor J Barani
Journal:  J Neurooncol       Date:  2011-10-18       Impact factor: 4.130

Review 6.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

Review 7.  Stereotactic radiosurgery of benign intracranial tumors.

Authors:  Bruce E Pollock
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

8.  Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.

Authors:  Okay Saydam; Ozlem Senol; Tieneke B M Schaaij-Visser; Thang V Pham; Sander R Piersma; Anat O Stemmer-Rachamimov; Thomas Wurdinger; Saskia M Peerdeman; Connie R Jimenez
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

9.  Hypofractionated stereotactic radiation therapy in skull base meningiomas.

Authors:  Pierina Navarria; Federico Pessina; Luca Cozzi; Elena Clerici; Elisa Villa; Anna Maria Ascolese; Fiorenza De Rose; Tiziana Comito; Ciro Franzese; Giuseppe D'Agostino; Francesca Lobefalo; Antonella Fogliata; Giacomo Reggiori; Maurizio Fornari; Stefano Tomatis; Lorenzo Bello; Marta Scorsetti
Journal:  J Neurooncol       Date:  2015-06-04       Impact factor: 4.130

10.  Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification.

Authors:  M Simon; J Boström; P Koch; J Schramm
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.